Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IBRX | US
-0.14
-3.92%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.43
3.42
3.48
3.38
ImmunityBio Inc. a clinical-stage biotechnology company engages in developing therapies and vaccines that complement harness and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803 vaccine technologies toll-Like receptor activating adjuvants natural killer cells and damage-associated molecular patterns inducers. The company also develops therapeutic agents which are in Phase II or III clinical trial for the treatment of liquid and solid tumors including bladder pancreatic and lung cancers as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris Inc.; and license agreements with LadRx Corporation GlobeImmune Inc. Access to Advanced Health Institute 3M Innovative Properties Company Sanford Health Shenzhen Beike Biotechnology Co. Ltd. Sorrento Therapeutics Inc. and Viracta Therapeutics Inc. The company is based in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
70.2%1 month
61.5%3 months
65.6%6 months
105.1%-
-
-
-1.43
2.25
-8.99
2.49K
-
-341.06M
2.39B
2.39B
-
-9.49K
-
2.45K
-
16.34
31.45
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.69
Range1M
0.81
Range3M
3.61
Rel. volume
0.58
Price X volume
5.29M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Verona Pharma plc | VRNA | Biotechnology | 32.01 | 2.60B | 11.49% | n/a | 129.87% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 42.99 | 2.46B | -1.15% | n/a | 0.51% |
SPRINGWORKS THERAPEUTICS INC. | SWTX | Biotechnology | 32.64 | 2.42B | -0.58% | n/a | 1.27% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -8.99 | 0.76 | Cheaper |
Ent. to Revenue | 2,488.53 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | - | 14.10 | - |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 65.64 | 74.67 | Par |
Debt to Equity | -1.43 | -1.82 | Expensive |
Debt to Assets | 2.25 | 0.26 | Expensive |
Market Cap | 2.39B | 3.73B | Emerging |